IΑSIS PHARMA showed its strong dedication in the field of Dermatology, by participating in the Annual Spring Day Conference of the Hellenic Society of Dermatology and Venereology, organized under the theme: “Therapeutic dilemmas in Dermatology – Venereology”. The event was held at Makedonia Palace Hotel, Thessaloniki, March 30th -31st 2018.

ΙΑSIS PHARMA introduced its new product, Modiwart®, promoted in the market from April 2018, in the form of cream (5%).
Modiwart®’s active ingredient is imiquimod, an innovative immunomodulator, with the following indications: external genital warts and anogenital (acuminate warts) in adults, small superficial basal cell carcinomas (sBCC) and clinically typical actinic keratoses.

A large number of dermatologists visited IASIS PHARMA stand, where they received information on two of the company’s main dermatological products:

Ιsotroin®, isotretinoin, a retinoid for the treatment of acne, is the only product of its kind in the Greek market available in 3 strenghts: soft caps of 10mg, 20mg and 40mg.

Combi®, a combination of miconazole + fluprednidene in the form of cream with excellent texture and the advantage of the 50g pack.